Dr. Morris on Novel Approaches With Radium-223 in mCRPC

Michael J. Morris, MD
Published: Friday, Nov 18, 2016



Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

While bone-targeted therapy such as radium-223 can be effective, combining it with another agent would maximize outcomes, Morris explains. The same could be said for tumor-directed therapy alone, he says, adding an environmental-related metaphor as an example. One of the challenges of using tumor-directed therapy would be "equivalent of trying to kill a billion mosquitos. You can try to do that or you can try to drain the swamp." Bone-directed therapy has the latter approach, he adds.

Utilizing a blend of both approaches will ultimately lead to an improved and more durable benefit in patients, Morris explains.


Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses what novel combinatorial approaches researchers will be explored with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

While bone-targeted therapy such as radium-223 can be effective, combining it with another agent would maximize outcomes, Morris explains. The same could be said for tumor-directed therapy alone, he says, adding an environmental-related metaphor as an example. One of the challenges of using tumor-directed therapy would be "equivalent of trying to kill a billion mosquitos. You can try to do that or you can try to drain the swamp." Bone-directed therapy has the latter approach, he adds.

Utilizing a blend of both approaches will ultimately lead to an improved and more durable benefit in patients, Morris explains.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x